DW1809-T2

DW1809-T2 is a pharmaceutical drug developed by Daewon Pharmaceutical Co., Ltd. It has been evaluated in clinical trials for its safety and pharmacokinetic characteristics, primarily in healthy adult volunteers, but also with relevance to conditions such as osteoarthritis, rheumatoid arthritis, back pain, and acute upper respiratory tract infection. The specific mechanism of action is not detailed in available sources; however, it appears to be related to the broader development pipeline of Daewon Pharmaceutical which includes COX inhibitors like pelubiprofen[3][5]. There is no evidence that DW1809-T2 itself is a COX inhibitor or that it contains pelubiprofen—rather, it may be a new chemical entity or formulation under investigation by the same company[3][5].